The effects of acute administration of propranolol and practolol on the uptake, content, release, and turnover of noradrenaline in the rat heart in vivo

  • B. Lemmer
  • R. Saller


The effect of the acute administration of (±)-, (+)-, and (−)-propranolol and practolol, respectively, on the cardiac turnover of noradrenaline was studied in male Wistar rats kept under controlled conditions of environmental lighting. Propranolol caused no or only minor effects on the turnover in concentrations of 0.001–0.1 mmoles/kg, whereas higher doses (0.2–0.4 mmoles/kg) decreased the noradrenaline turnover in rat hearts concomitantly with toxic signs from the CNS. The endogenous noradrenaline content was not changed by any concentration of propranolol. Practolol (0.1–0.4 mmoles/kg) did not influence the cardiac noradrenaline turnover, but, like an indirectly acting sympathomimetic drug, released noradrenaline.

Key words

Noradrenaline Turnover Rat Heart Propranolol Practolol Noradrenaline Content 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abrams, W. B., Solomon, H. M.: The human blood platelet as a pharmacological model for the adrenergic neuron. The uptake and release of norepinephrine. Clin. Pharmacol. Ther.10, 702–709 (1969)Google Scholar
  2. Anton, A. H., Sayre, D. F.: A study of the factors affecting the aluminium oxidetrihydroxyindole procedure for the analysis of catecholamines. J. Pharmacol. exp. Ther.138, 360–374 (1962)Google Scholar
  3. Bainbridge, J. G., Greenwood, D. T.: Tranquillizing effects of propranolol demonstrated in rats. Neuropharmacology10, 453–458 (1971)Google Scholar
  4. Baird, J. R. C., Linnell, J.: The assesment of β-adrenoceptor blocking potency and cardioselectivity in vitro and in vivo. J. Pharm. Pharmacol.24, 880–885 (1972)Google Scholar
  5. Black, J. W., Duncan, W. A. M., Shanks, R. G.: Comparison of some properties of pronethalol and propranolol. Brit. J. Pharmacol.25, 577–591 (1965)Google Scholar
  6. Brick, J., Hutchinson, K. J., Mc Devitt, D. G., Roddie, I. C., Shanks, R. G.: Comparison of the effects of I.C.I. 50172 and propranolol on the cardiovascular responses to adrenaline, isoprenaline and exercise. Brit. J. Pharmacol.34, 127–140 (1968)Google Scholar
  7. Chang, C. C.: A sensitive method for spectrofluometric assay of catecholamines. Int. J. Neuropharmacol.3, 643–649 (1964)Google Scholar
  8. Chang, C. C., Wang, W.-H.: Antagonism by propranolol of the inhibitory effect of phenoxybenzamine on noradrenaline uptake in vivo. J. Pharm. Pharmacol.23, 911–917 (1971)Google Scholar
  9. Costa, E.: Simple neuronal models to estimate turnover rate of noradrenergic transmitters in vivo. In: Biochemistry of simple neuronal models. Advanc. Biochem. Pharmacol.2, 169–204 (1970)Google Scholar
  10. Dollery, C. T., Paterson, J. W., Conolly, M. E.: Clinical pharmacology of beta-receptor-blocking drugs. Clin. Pharmacol. Ther.10, 765–799 (1969)Google Scholar
  11. Dunlop, D., Shanks, R. G.: Selective blockade of adrenoceptive beta receptor in the heart. Brit. J. Pharmacol.32, 201–218 (1968)Google Scholar
  12. Estler, C. J., Ammon, H. P. T.: Absence of central nervous system effects of practolol (ICI 50, 172; 4-(2-hydroxy-3-isopropylaminopropoxy)-acetanilide), a new adrenergic β-receptor blocking drug. J. Pharm. Pharmacol.21, 554–555 (1969)Google Scholar
  13. Fabian, H. E. M., Izquierdo, J. A.: Effect of β-adrenergic blocking agents on the spontaneous motility in mice. Arzneimittel-Forsch. (Drug Res.)22, 1375–1376 (1972)Google Scholar
  14. Farrant, J., Harvey, J. A., Pennefather, J. N.: The influence of phenoxybenzamine on the storage of noradrenaline in rat and cat tissues. Brit. J. Pharmacol.22, 104–122 (1964)Google Scholar
  15. Fitzgerald, J. D.: Perspectives in adrenergic beta-receptor blockade. Clin. Pharmacol. Ther.10, 292–306 (1969)Google Scholar
  16. Flacke, J. W., Osgood, P. F., Bendixen, H. H.: Propranolol and isoproterenol in dogs deprived of sympathetic nerve activity. J. Pharmacol. exp. Ther.158, 519–530 (1967)Google Scholar
  17. Foo, J. W., Jowett, A., Stafford, A.: The effect of some β-adrenoceptor blocking drugs on the uptake and release of noradrenaline by the heart. Brit. J. Pharmacol.34, 141–147 (1968)Google Scholar
  18. Grobecker, H., Lemmer, B., Hellenbrecht, D., Wiethold, G.: Inhibition by antiarrhythmic andβ-sympatholytic drugs of serotonin uptake by human platelets: Experiments in vitro and in vivo. Europ. J. clin. Pharmacol.5, 145–150 (1973)Google Scholar
  19. Hellenbrecht, D., Lemmer, B., Wiethold, G., Grobecker, H.: Measurement of hydrophobicity, surface activity, local anaesthesic and myocardial conduction velocity as quantitative parameters of the non-specific membrane affinity of nine β-adrenergic blocking agents. Naunyn-Schmiedeberg's Arch. Pharmacol.277, 221–226 (1973)Google Scholar
  20. Hermansen, K.; Effect of different β-adrenergic receptor blocking agents on hexobarbital induced narcosis in mice. Acta pharmacol. (Kbh.)27, 453–460 (1969)Google Scholar
  21. Iversen, L. L.: The inhibition of noradrenaline uptake by drugs. Advanc. Drug Res.2, 5–23 (1965)Google Scholar
  22. Iversen, L. L., Jarrott, B., Simmonds, M. H.: Differences in the uptake, storage and metabolism of (+)-and (−)-noradrenaline. Brit. J. Pharmacol.43, 845–855 (1971)Google Scholar
  23. Klinge, E., Aro, S.: Effect of beta-adrenergic blocking compounds on tissue catecholamine levels. Europ. J. Pharmacol.14, 124–129 (1971)Google Scholar
  24. Lemmer, B.: Effects of amantadine and amphetamine on serotonin uptake and release by human blood platelets. Europ. J. Pharmacol.21, 183–188 (1973)Google Scholar
  25. Lemmer, B., Saller, R.: Difference in the turnover of nordrenaline in rat heart during day and night. Naunyn-Schmiedeberg's Arch. Pharmacol.278, 107–109 (1973)Google Scholar
  26. Lemmer, B., Saller, R.: Influence of light and darkness on the turnover of noradrenaline in the rat heart. Naunyn-Schmiedeberg's Arch. Pharmacol.282, 75–84 (1974)Google Scholar
  27. Lemmer, B., Wiethold, G., Hellenbrecht, D., Bak, I. J., Grobecker, H.: Human blood platelets as a cellular models for investigation of membrane active drugs: Beta-adrenergic blocking agents. Naunyn-Schmiedeberg's Arch. Pharmacol.275, 299–313 (1972)Google Scholar
  28. Leszkovszky, G., Tardos, L.: Some effects of propranolol on the central nervous system. J. Pharm. Pharmacol.17, 518–519 (1965)Google Scholar
  29. Lindmar, R., Muscholl, E.: Die Wirkung von Pharmaka auf die Elimination von Noradrenalin aus der Perfusionsflüssigkeit und die Noradrenalin-Aufnahme in das isolierte Herz. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak.247, 469–492 (1964)Google Scholar
  30. Mazurkiewicz-Kwilecki, I. M., Romagudi, A.: Cardiac catecholamine levels after chronic treatment with β-adrenergic blocking agents. J. Pharm. Pharmacol.22, 235–237 (1970)Google Scholar
  31. Morales-Aguilera, Vaughan Williams, E. M.: The effects on cardiac muscle of β-receptor antagonists in relation to their activity as local anaesthetics. Brit. J. Pharmacol.24, 332–338 (1965)Google Scholar
  32. Murmann, W., Almirante, A., Saccani-Guelfi, M.: Central nervous system effects of four β-adrenergic receptor blocking agents. J. Pharm. Pharmacol.118, 317–318 (1966)Google Scholar
  33. Neff, N. H., Tozer, T. N., Hammer, W., Costa, E., Brodie, B. B.: Application of steady-state kinetics to the uptake and decline of3H-NE in the rat heart. J. Pharmacol. exp. Ther.160, 48–52 (1968)Google Scholar
  34. Refsum, H., Landmark, K.: The action of practolol on isolated rat atrium. Acta pharmacol. (Kbh.)31, 97–106 (1972)Google Scholar
  35. Starke, K., Schümann, H. J.: Interactions of angiotensin, phenoxybenzamine and propranolol on noradrenaline release during sympathic nerve stimulation. Europ. J. Pharmacol.18, 27–30 (1972)Google Scholar
  36. Werner, W., Wagner, J., Schümann, H. J.: Beeinflussung der Noradrenalinabgabe aus isolierten Kaninchenherzen durch β-Adrenolytica unter sympathischer Nervenreizung. Naunyn-Schmiedebergs Arch. Pharmak.268, 102–113 (1971)Google Scholar
  37. Westfall, T. C.: Accumulation of norepinephrine in rat tissue following treatment with three beta-adrenergic antagonists. Arch. int. Pharmacodyn.167, 69–79 (1967)Google Scholar
  38. Wiethold, G., Hellenbrecht, D., Lemmer, B., Palm, D.: Membrane effects of beta-adrenergic blocking agents: Investigations with the fluorescence probe 1-anilino-8-naphthalene sulfonate (ANS) and antihemolytic activities. Biochem. Pharmacol.22, 1437–1449 (1973)Google Scholar

Copyright information

© Springer-Verlag 1974

Authors and Affiliations

  • B. Lemmer
    • 1
  • R. Saller
    • 1
  1. 1.Zentrum der PharmakologieJohann Wolfgang Goethe-Universität Frankfurt am MainGermany

Personalised recommendations